Galena Biopharma (GALE) Reports Q4 Loss Per Share of 6c, Reiterates FY15 Rev. Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Galena Biopharma (GALE) PT Lowered at Needham & Company But Still Sees Shares Doubling
March 6, 2015 10:00 AM ESTNeedham & Company analyst Chad Messer lowered his price target on Galena Biopharma (NASDAQ: GALE) to $4.00 (from $7.00) but maintained his Buy rating. The new price target represents 100% upside from yesterday's closing price.
Messer commented, "Abstral put in its best quarter since launch with $3.2... More
Roth Affirms Galena Biopharma (GALE) at 'Buy' Following Q4 Report; Still Sees FY15/FY16 as Busy Time Frame
March 6, 2015 8:42 AM ESTRoth Capital reiterates its Buy rating and $8 price target on Galena Biopharma (Nasdaq: GALE) following Q4, FY14 results reported Thursday night.
Analyst Joseph Pantginis noted that Galena's FY14 revenue of $9.32 million and loss of $0.31 per share compare with the firm's outlook calling for revenue of $8.5 million and loss of $0.35 per share.
Pantginis offered the following post-report commentary: 2015 represents a... More
